clinical

Evidium Announces $22M Funding Close to Scale Computational Medical Knowledge

SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Evidium, a healthcare AI company, is building AI based on computational knowledge…

1 month ago

GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Regenerative Technology in ACLF

EVerZom’s investigational drug candidate EViv, developed to treat ACLF, using its proprietary exosome platform, represents a novel approach to regenerative…

1 month ago

NCCN Celebrates Expanding Access to Cancer Treatment in Africa at 2025 AORTIC Meeting with New NCCN Adaptations for Sub-Saharan Africa

Updated cancer treatment guidelines reflect significant progress in cancer care delivery through ongoing collaborative efforts to strengthen oncology resources across…

1 month ago

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

November 08, 2025 17:13 ET  | Source: Intellia Therapeutics, Inc. Deep, stable and durable reductions in kallikrein observed Among 32 patients…

1 month ago

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

THE WOODLANDS, Texas, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that new sotagliflozin clinical…

1 month ago

INTREPID Alliance Launches Antiviral Toolbox to Support Global Research Community

Open-access resource includes Registry of Antiviral Compound Libraries to help catalyze drug discovery for priority viruses of pandemic and endemic…

1 month ago

Baylor Genetics to Highlight Genetic Testing Use Cases and Advancements in Rare Disease at The National Society of Genetic Counselors 44th Annual Conference

HOUSTON, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, will…

1 month ago

LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE

Results presented at the 17th World Stroke Congress (WSC 2025) LT3001(Odatroltide)-202 phase 2b study met primary endpoint. No symptomatic intracranial…

2 months ago

FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

October 31, 2025 16:30 ET  | Source: FibroBiologics, Inc. Advancing preparations to begin manufacturing of fibroblast-based spheroids product candidate, CYWC628,…

2 months ago

ArkBio Initiates Phase II Clinical Trial of AK0610, a Preventive Monoclonal Antibody for Respiratory Syncytial Virus Infection

SHANGHAI, Oct. 30, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced the initiation of a Phase II…

2 months ago